Introduction
The Ig superfamily includes many leukocyte membrane molecules with important functions including leukocyte adhesion, antigen recognition and stimulation of an immune response. Several members of the Ig superfamily can be grouped into smaller families that have related genes or, alternatively, several isoforms of different molecules, such as the FcγR (CD16 and CD64) (1), the FcαR (CD89) (2) and the killer cell inhibitory receptor (KIR) molecules (3) . Whilst the common component of these isoforms may be recognized by the same mAb they may have different functional capabilities. Some of these molecules, i.e. TCR-CD3 (4), B cell antigen receptor (5) , and some FcR including FcεRI, FcγRIIA and FcγRIIIA, are involved in cell activation mediated by the cytoplasmic motifs known as immunoreceptor tyrosine-based activation motifs (ITAM) (1, 6) . A group of receptors with an inhibitory effect on cellular activation, following cross-linking with ligand, include Correspondence to: G. Clark Transmitting editor: A. McMichael Received 9 October 1997, accepted 13 March 1998 molecules containing immunoreceptor tyrosine-based inhibitory motifs (ITIM); KIR, FcγRIIB and CD22b (6) (7) (8) (9) . The mechanism for FcγRIIB-dependent inhibition has been studied in most detail. Inhibition of cellular activation requires co-aggregation of FcγRIIB with ITAM containing molecules leading to phosphorylation of the tyrosine residues. Once phosphorylated, FcγRIIB is a potential ligand for protein tyrosine phosphatases including SHP-1, SHP-2 and SHIP (6) . The CMRF-35 antigen is broadly expressed on leukocytes including large granular lymphocytes, monocytes, macrophages and granulocytes (10) . In addition, it is expressed by some but not all peripheral blood lymphocytes (PBL) and by relatively few tonsillar lymphocytes. Expression cloning was used to isolate a cDNA that encoded the CMRF-35 epitope (11) . It has a single V-like domain, an extended membrane proximal region, a transmembrane domain and a cytoplasmic region. The Ig-like domain of the CMRF-35 cDNA is most closely related to the Ig binding domains of the FcR for polymeric IgA and IgM. However, analysis of the expression of CMRF-35 transcripts by both Northern blot and RT-PCR indicated that this mRNA is not expressed in all the cell lines which bind the CMRF-35 mAb. This suggested the presence of additional isoforms expressing the CMRF-35 binding antigenic epitope. We now describe a novel leukocyte surface molecule, CMRF-35-H9, which is also a member of the Ig superfamily. CMRF-35-H9 shows considerable similarity to the V-like domain of CMRF-35 but otherwise bears little sequence similarity to this first molecule. The cytoplasmic tail of CMRF-35-H9 bears a motif with similarities to the ITIM motifs found in a number of molecules that perform important inhibitory functions following cellular activation.
Methods

mAb
The following mAb were used in this study: CMRF-35 mAb (IgG2a) (10), CMRF-31 (CD14, IgG2a, this laboratory), CMRF-7 (CD15, IgM, this laboratory), CMRF-15 (IgM, this laboratory), Sal4 (IgG2b), X63 (IgG1) and Sal5 (IgG2a, all kindly provided by Dr H Zola, Adelaide, Australia). The CD3 (OKT3), CD16 (HuNK2) and CD8 (OKT8) were obtained from the ATCC (Rockville, MD). Directly labeled mAb used were CD3-phycoerythrin (PE), CD14-PE, IgG1-PE and IgG2a-PE (Becton Dickinson, Mountain View, Ca).
Cell lines
The early hemopoietic cell lines KG1 and HEL, the myeloid cell lines K562, U937, HL60 and THP-1, the Hodgkin's-derived cell lines L428, HOLM2 and KMH2 the B lymphoblastoid cell line Mann, and the acute T cell leukemic lines Jurkat and Molt4 were maintained in RPMI 1640 supplemented with 10% FCS (Life Technologies, Gaithersburg, MD). The Hodgkin'sderived cell line, L428, was obtained from Dr V. Diehl (Klinik for Innere Medizine, Cologne, Germany).
Transfections
The cDNAs were expressed in the pcDNA3 mammalian expression vector (Invitrogen, Leek, Netherlands). Linearized plasmid DNA was electroporated into Jurkat cells (960 mF, 250V) and grown in RPMI/10% FCS supplemented with 600 mg/ml Geneticin (Life Technologies).
Library screening
A λgt11 cDNA library made from the erythroleukemic cell line, HEL, was kindly supplied by Dr M. Bodger. The library was screened by hybridization using the 871 bp XbaI fragment of the CMRF-35 cDNA as a probe. The probe was labeled with [ 32 P]dCTP using an RTS Radprime Kit (Life Technologies). Three rounds of screening were performed, and then DNA was isolated from purified bacteriophage following treatment with EDTA-SDS and proteinase K (12) . Bacteriophage DNA was digested with EcoRI to release the inserts which were purified and subcloned into the SK ϩ Bluescript vector (Stratagene, La Jolla, CA).
Sequencing
Nucleic acid sequencing of the CMRF-35-H9 cDNA was performed by dideoxy sequencing using a Sequenase kit (Amersham, Amersham, UK). The cDNA was sequenced in both directions using sequence-specific oligonucleotide primers as appropriate.
Production of antisera
Peptides corresponding to sequences in the cytoplasmic regions of each putative protein were synthesized and coupled to diphtheria toxin (Chiron, Melbourne, Australia For intracellular staining, cells were permeabilized using a Fix and Perm cell permeabilization kit (Caltag, San Francisco, CA) according to the manufacturer's instructions. Briefly, 10 6 PBMC were incubated at room temperature with 100 µl fixative A for 15 min. The cells were washed in PBS, resuspended in 100 µl reagent B/10% sheep serum and labeled as above with peptide antisera. Control antisera were made by preblocking with the immunizing peptide. Cells were washed twice in PBS/0.1% BSA and labeled with human adsorbed, FITC-goat anti-rabbit Ig. Labeled cells were blocked with 10% normal mouse serum before incubation with CD3-PE, CD14-PE or isotype control mAb.
RT-PCR
Total RNA was prepared from frozen cell pellets using a NP-40 lysis protocol (13) . Briefly, cells (Ͻ10 7 ) were thawed in 400 µl NP-40 lysis buffer and incubated on ice for 5 min. Nuclei were pelleted by centrifugation, SDS was added to a final concentration of 0.5% and EDTA to a final concentration of 0.5 mM. The RNA was extracted with phenol-CHCl 3 and precipitated. Total RNA was resuspended in H 2 O and residual genomic DNA was digested with RNase-free DNase I (Boehringer Mannheim, Mannheim, Germany) at 37°C for 10 min. The cDNA was made from RNA prepared from equivalent numbers of cells. RNA was annealed to oligo-dT primers and reverse transcribed with Superscript II RNase H -reverse transcriptase (Life Technologies) at 42°C for 1 h. Following heat inactivation at 70°C for 10 min, RNA was digested with RNase H (Boehringer Mannheim) at 37°C for 30 min. The cDNA was diluted with H 2 O. Amplification with Taq polymerase (Boehringer Mannheim) by PCR used 2.5 ml of cDNA per 25 ml reaction.
Analysis of the CMRF-35 gene product by RT-PCR used the 5Ј primer H9d (5Ј-GATTGTGGAGACCAAAGG-3Ј) and the 3Ј primer 35-J (5Ј-GCTTTCTGGTCACGCTGG-3Ј). Seminested RT-PCR analysis for CMRF-35 used the 5Ј primer H9d and the 3Ј primer 35-D (5Ј-CCAGCATGCTCAGGAGCAG-3Ј) followed by semi-nested amplification with 35-C (5Ј-AGAGCTCCATGGGCACCTC-3Ј) and 35-D which produced a fragment of 170 bp. CMRF-35-H9 was amplified with H9d and H9f (5Ј-AGAAGCAGCAACAATGCC-3Ј) followed by a semi-nested amplification with H9e (5Ј-GACCTCAACAATCA-CAAC-3Ј) and H9f to give a PCR product of 155 bp. To ensure that the PCR amplification for each gene was of equivalent efficiency each primer set was used to amplify molar equivalents of cDNA plasmid template. All products were detected at the same cycle number. In addition, each semi-nested PCR reaction was performed on different amounts of template. Each amplification detected product from 200 pg of template after 25 cycles. Thus the semi-nested PCR reactions performed here were able to detect the gene products with similar efficiencies.
All products were transferred to nylon membranes by Southern blotting and probed with specific oligonucleotides. Oligonucleotide probes were labeled with digoxigenin-11-dd-UTP using terminal transferase according to the manufacturer's protocols (Boehringer Mannheim). Integrity of the cDNA was confirmed by RT-PCR analysis of human GAPDH using the following primers; 5Ј primer (5Ј-ATGGGGAAGGTGAA-GGTCGGA-3Ј) and 3Ј primer (5Ј-AGGGGCCATCCACAGTCT-TCTG-3Ј) (14) . Oligonucleotides were either synthesized inhouse or by Life Technologies.
Results
Expression of CMRF-35 detected by mAb reactivity and RT-PCR data
The CMRF-35 mAb was used previously to isolate a cDNA by expression cloning (11) . The cDNA expressed a protein following transient transfection in COS-7 cells which bound the CMRF-35 mAb as determined by flow cytometry. Northern blot analysis identified expression of the mRNA in many but not all of the cell lines that had been shown to react with the CMRF-35 mAb by flow cytometry (10) . We therefore undertook additional analysis to clarify the results using RT-PCR analysis.
Cell lines that both bound and did not bind the CMRF-35 mAb were analyzed. The presence of the CMRF-35 cell surface antigen was demonstrated by flow cytometry on the K562, U937 and HEL cell lines but not on the L428 cell line (Fig. 1A) . RT-PCR, using primers that amplified across an intron between the extracellular and transmembrane regions (unpublished data, G. J. C.), identified specific CMRF-35 mRNA in the HEL and U937 cell lines but no specific CMRF-35 product was expressed in K562 or L428 (Fig. 1B) . The specificity of this PCR was confirmed by hybridization of a specific oligonucleotide probe to the RT-PCR products and analysis of GAPDH control primers confirmed the integrity of all cDNA. This data suggested that binding of CMRF-35 mAb to hemopoietic cells was not confined solely to the product of the known CMRF-35 cDNA and that a second molecule which bound the mAb was present on K562. Although the HEL cell line expressed similar amounts of CMRF-35 mRNA as detected by RT-PCR, the flow cytometry profile often showed a broader, sometimes bifid, peak compared to other cell lines suggesting that HEL, too, might have additional reactivity with the mAb.
Isolation of the CMRF-35-H9 cDNA
A λgt11 HEL cDNA library was screened by hybridization with the 871 bp XbaI fragment of the CMRF-35 cDNA. After three rounds of screening three plaques were chosen for further analysis. All three plaques hybridized with the CMRF-35 cDNA. The DNA inserts were purified from the phage DNA and were analyzed by restriction endonuclease digestion. This indicated that one clone, CMRF-35-H9, had a different restriction map to the original cDNA. Southern blots of the digested DNA were probed with a number of oligonucleotides specific for the different exons of the CMRF-35 protein (unpublished data, G. J. C.). Only oligonucleotides to the Ig-like domain and not the membrane proximal, transmembrane and cytoplasmic regions of the CMRF-35 cDNA hybridized to the CMRF-35-H9 cDNA. The restriction maps of the two cDNAs were distinct and their differences were confirmed by nucleotide sequencing. Thus CMRF-35 cDNA and CMRF-35-H9 cDNA represent two entirely different sequences.
The sequence of the CMRF-35-H9 cDNA has a single open reading frame of 980 nucleotides with a 5Ј untranslated region of 80 nucleotides and a 3Ј untranslated region of 651 nucleotides. A consensus site for polyadenylation was not present indicating that the clone is not full length.
A Kyte-Doolittle plot analysis suggests that the molecule encodes a type I transmembrane protein (Fig. 2) . It has a hydrophobic leader sequence of 13 amino acids with a consensus cleavage site (15) followed by an extracellular region of 163 amino acids, a hydrophobic transmembrane domain of 24 amino acids and a cytoplasmic region of 100 amino acids. Like CMRF-35, the CMRF-35-H9 extracellular region has a single Ig V-like domain. In particular, this sequence differed by only 18 amino acids from the Ig-like extracellular domain of the CMRF-35 cDNA (Fig. 2) . The amino acid differences between the CMRF-35 and CMRF-35-H9 Ig domains indicated that the Ig-like sequences are not encoded by the same exon. Previously, the CMRF-35 cDNA was found to be most similar (~30% amino acid identity) to the V1 and V4 domains of the Fc receptor for polymeric IgA and IgM (11) . The region of similarity between CMRF-35 and CMRF-35-H9 is in the region that shares sequence similarity with the poly Ig receptor. There are two sites for N-linked glycosylation in this region that are conserved between the two sequences. The remainder of the sequences are quite different. The CMRF-35-H9 membrane proximal region of 45 amino acids contains a number of serine and threonine residues suggesting the presence of O-linked glycosylation. In addition, there are a number of proline residues indicating that this hinge region may form a relatively rigid structure. Unlike the CMRF-35 transmembrane sequence, the CMRF-35-H9 sequence does not contain a charged residue in the transmembrane region, suggesting that the two molecules have different expression characteristics.
The 100 amino acid cytoplasmic region of the CMRF-35-H9 cDNA is relatively long compared to that of the CMRF-35 cDNA (18 amino acids). In addition, the CMRF-35-H9 cytoplasmic sequence contains four tyrosine-containing motifs similar to the motifs found in the cytoplasmic domains of a number of molecules involved in intracellular signaling and phosphorylation events. The amino acid sequences surrounding Tyr233, 256, 269 and 285 are aligned with the ITIM consensus sequence and the amino acid sequences of ITIMs from other molecules (16) (17) (18) (19) in Fig. 3 . Three of these motifs surrounding Tyr233, 256 and 269 conform to the ITIM consensus sequence. The fourth potential ITIM motif (surrounding Tyr285) has a conservative substitution of isoleucine for valine or leucine but does not conform strictly to the currently accepted consensus sequence. The presence of these motifs suggests that CMRF-35-H9 may have an inhibitory signaling role (6, 9) .
A second di-leucine motif (residues 237 and 238) is also found in the CMRF-35-H9 cytoplasmic domain. This motif is associated with endocytosis and delivery to lysosomes of other molecules including CD3γ and CD3δ chains (20) . The CMRF-35-H9 cDNA encodes a molecule that is recognized by the CMRF-35 mAb Stable transfectants were generated expressing either the CMRF-35 or CMRF-35-H9 cDNAs to establish and confirm the reactivity of the mAb with each gene product. Binding of the mAb to Jurkat cells expressing the CMRF-35 cDNA but not to cells transfected with the vector alone confirmed reactivity with the original gene product (Fig. 4) . Reactivity of the mAb with transfectants expressing the CMRF-35-H9 cDNA confirmed that this new cDNA encodes a second molecule recognized by the CMRF-35 mAb (Fig. 4D) . The epitope that is recognized by the mAb has not been mapped; however, the sequences of the two cDNAs are similar only in the Iglike domain and thus the CMRF-35 mAb probably recognizes an epitope in this region.
Both proteins are expressed in normal PBMC
To determine if the protein product of CMRF-35-H9 is expressed in normal PBMC, polyclonal antisera were raised against peptides representing part of the cytoplasmic region of the CMRF-35-H9 and CMRF-35 proteins. Each polyclonal serum reacted specifically with the immunizing peptide but not with the peptide to the other protein or an irrelevant peptide sequence as determined by ELISA (data not shown). Surface and intracellular staining were assessed by flow cytometry (Fig. 5) . Neither polyclonal serum bound to the surface of unfixed cells (data not shown). The CMRF-35 mAb, which recognizes both protein products, binds to PBMC; however, the actual amount of reactivity differs markedly between different samples. As expected, both the CMRF-35-H9 peptide specific serum and the CMRF-35 peptide-specific serum bind to subpopulations of PBMC.
Different leukocyte populations were analyzed after double labeling by flow cytometry. The CMRF-35 mAb binds to most CD14 ϩ monocytes (10) . Both the CMRF-35-H9 peptide- 
a Expression detected by flow cytometry.
Mann and HEL. However, several myeloid-derived cell lines expressed only one of the transcripts; K562 expressed only the CMRF-35-H9 transcript whilst U937 and THP-1 expressed only the CMRF-35 transcript ( Table 1 ). The differential expression of the two transcripts suggests that they are not regulated by the same promoter and are thus the products of distinct 
genes. This has been confirmed by characterization of the CMRF-35 and CMRF-35-H9 genes (in preparation, G. J. C.). RT-PCR analysis was performed on purified normal PBL populations. Both the CMRF-35-H9 and CMRF-35 mRNAs were expressed by CD3 ϩ T lymphocytes, CD15 ϩ granulocytes, CD16 ϩ NK cells, CD14 ϩ myeloid cells and unactivated dendritic cell populations (Table 2) .
To document this further, semi-quantitative analysis of each transcript was performed by removing samples from the RT-PCR after varying cycle numbers. This identified the transcript present in greater abundance as the PCR product that could be detected at the lowest cycle number (13) . These experiments (Fig. 6 ) indicated CD3 ϩ T lymphocytes, and the CD4 ϩ and CD8 ϩ T lymphocyte subpopulations, express relatively more of the CMRF-35-H9 mRNA than that of the CMRF-35 mRNA. However, the CD14 ϩ myeloid population expressed relatively more of the CMRF-35 transcript than that of CMRF-35-H9. As cDNA prepared from one population of cells is used as template for both PCR, comparison of expression within a population is valid.
Discussion
The CMRF-35 mAb recognizes an antigenic epitope that is widely expressed on the surface of leukocytes from all hemopoietic lineages. The cDNA for this molecule was isolated previously by expression cloning (11) (1) or alternatively that the molecule is targeted for retention and degradation within the endoplasmic reticulum (24) . Other molecules of the FcR family that also have signaling capabilities have been shown to associate at the membrane with a common γ chain (1) . Whether the CMRF-35 molecule also associates with a common γ chain is presently being studied.
The two molecules have very different cytoplasmic sequences. The sequence of the cytoplasmic domain of the CMRF-35-H9 molecule encodes four tyrosine motifs including three consensus ITIM motifs and a fourth possible ITIM motif. Similar motifs have been identified in a number of other cell surface receptors that have been shown to have signaling capabilities including CD16a, CD32, the KIR and NKAT receptors (3, 6, 8) , and more recently other novel members of the Ig superfamily (16, 17, 25, 26) . The presence of signaling motifs in the CMRF-35-H9 sequence strongly suggests that this molecule may play a role in intracellular cell signaling and this is currently under investigation. The CMRF-35 transmembrane sequence does not contain tyrosine residues, suggesting that this molecule may have an entirely different signaling role to CMRF-35-H9 despite a similar extracellular (ligand?) binding domain. It has been noted that members of the ITIM-bearing receptor family have counterpart molecules that have highly similar extracellular domains but lack the presence of cytoplasmic ITIM motifs (9) . The cytoplasmic domains of these counterpart proteins are, in general, shorter, whereas their transmembrane regions typically include a charged amino acid residue. Furthermore the non-inhibitory/activating counterparts are the products of separate genes. The CMRF-35-H9 and CMRF-35 molecules may also be members of this family.
In addition to the tyrosine-containing motifs, the CMRF-35-H9 cytoplasmic region has a di-leucine motif. This motif is associated with endocytosis and delivery to lysosomes of other molecules including CD3γ and CD3δ chains (20) . The functional significance of the di-leucine motif and the putative ITIM motifs is under investigation.
The differential expression of the CMRF-35-H9 and CMRF-35 molecules again suggests that each molecule may play very different roles in leukocyte function. At the mRNA level, CMRF-35-H9 is the predominant CMRF-35 mAb binding molecule expressed on T lymphocytes, whereas the CMRF-35 molecule is predicted to play a more prominent role on monocytes. Although we could confirm the expression by most monocytes and by a subpopulation of T lymphocytes of both molecules at the protein level, more detailed analysis will require new discriminating cell surface binding reagents to be developed. Therefore, whether or not the CMRF-35-H9 and CMRF-35 molecules define mutually exclusive subpopulations of monocytes has yet to be determined.
Little information regarding the regulation of either molecule is known. Nonetheless previous data suggested considerable up-and down-regulation of the cell surface molecules detected with the CMRF-35 mAb (10) indicating once again that these molecules may have a dynamic role in leukocyte function. There is also considerable variation in expression of the CMRF-35-H9 and CMRF-35 molecules between different individuals, and this too may prove to have some physiological significance. It will be of interest to determine how these molecules relate to other significant cell membrane molecules and whether they interact with each other to regulate function. It is hoped that the new reagents we are developing will facilitate further studies characterizing the tissue distribution, the regulation of expression and biochemical data of the CMRF-35-H9 and CMRF-35 molecules. These additional tools are essential to investigate potential Ig-binding functions of the CMRF-35-H9 and CMRF-35 molecules.
